BAJAJ BROKING

Notification close image
No new Notification messages
card image
Anondita Medicare IPO is Open!
Apply for the Anondita Medicare IPO through UPI in just minutes.
delete image
card image
Start your SIP with just ₹100
Choose from 4,000+ Mutual Funds on Bajaj Broking
delete image
card image
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
delete image
card image
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
delete image
card image
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
delete image

14013

530239

SUVEN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

Suven Life Sciences performance

Today’s low

Today’s high

₹ 229.05 ₹ 236.00
₹ 230.05

52 week low

52 week high

₹ 102.50 ₹ 299.99
₹ 230.05

Open Price

₹ 230.55

Prev. Close

₹ 234.35

Volume (Shares)

36444.00

Total traded value

₹ 83.83

Upper Circuit

₹ 246.05

Lower Circuit

₹ 222.65

info

Suven Life Sciences Share Price Update

As of the latest trading session, Suven Life Sciences share price is currently at ₹ 230.75, which is down by ₹ -3.60 from its previous closing. Today, the stock has fluctuated between ₹ 229.05 and ₹ 236.00. Over the past year, Suven Life Sciences has achieved a return of 61.99 %. In the last month alone, the return has been -18.03 %. Read More...

Investment Returns

Over 1 Month -18.03% Over 3 Months 14.15% Over 6 Months 98.18% Over 1 Year 61.99%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

Suven Life Sciences fundamentals


  • Market cap (Cr)

    5,022.20

  • P/E Ratio (TTM)

    -93.53

  • Beta

    0.95

  • Book Value / share

    36.66

  • Return on equity

    -6.33%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -14.78

info icon alternate text
  • Market cap (Cr)

    5,016.80

  • P/E Ratio (TTM)

    -93.53

  • Beta

    0.80

  • Book Value / share

    36.66

  • Return on equity

    -6.33%

  • EPS (TTM)

    0.00

  • Dividend yield

    0.00%

  • Net profit/quarter (Cr)

    -14.78

info icon alternate text

Suven Life Sciences Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars JUN 2025 (Values in Cr)
Revenue 1.87
Operating Expense 17.23
Net Profit -14.78
Net Profit Margin (%) -790.37
Earnings Per Share (EPS) -0.68
EBITDA -13.41
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 1.47
Operating Expense 17.73
Net Profit -15.07
Net Profit Margin (%) -1025.17
Earnings Per Share (EPS) -0.69
EBITDA -13.72
Effective Tax Rate (%) 0.00
Particulars DEC 2024 (Values in Cr)
Revenue 1.61
Operating Expense 16.45
Net Profit -13.27
Net Profit Margin (%) -824.22
Earnings Per Share (EPS) -0.61
EBITDA -11.73
Effective Tax Rate (%) 0.00
Particulars SEP 2024 (Values in Cr)
Revenue 2.57
Operating Expense 17.68
Net Profit -11.07
Net Profit Margin (%) -430.73
Earnings Per Share (EPS) -0.51
EBITDA -9.59
Effective Tax Rate (%) 0.00
Particulars JUN 2024 (Values in Cr)
Revenue 1.01
Operating Expense 12.60
Net Profit -7.67
Net Profit Margin (%) -759.40
Earnings Per Share (EPS) -0.35
EBITDA -6.16
Effective Tax Rate (%) 0.00
Particulars MAR 2025 (Values in Cr)
Revenue 6.66
Operating Expense 64.46
Net Profit -47.08
Net Profit Margin (%) -706.90
Earnings Per Share (EPS) -2.16
EBITDA -41.21
Effective Tax Rate (%) 0.00
Particulars MAR 2024 (Values in Cr)
Revenue 11.69
Operating Expense 49.29
Net Profit -8.01
Net Profit Margin (%) -68.52
Earnings Per Share (EPS) -0.37
EBITDA -2.34
Effective Tax Rate (%) 11.09
Particulars MAR 2023 (Values in Cr)
Revenue 13.54
Operating Expense 48.12
Net Profit -20.13
Net Profit Margin (%) -148.67
Earnings Per Share (EPS) -1.13
EBITDA -13.30
Effective Tax Rate (%) 0.00
Particulars MAR 2022 (Values in Cr)
Revenue 11.84
Operating Expense 53.41
Net Profit -36.25
Net Profit Margin (%) -306.16
Earnings Per Share (EPS) -2.69
EBITDA -31.33
Effective Tax Rate (%) 0.00
Particulars MAR 2021 (Values in Cr)
Revenue 13.48
Operating Expense 49.19
Net Profit -22.63
Net Profit Margin (%) -167.87
Earnings Per Share (EPS) -1.78
EBITDA -22.78
Effective Tax Rate (%) 19.03
Particulars MAR 2025 (Values in Cr)
Book Value / Share 5.04
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -2323.57
Particulars MAR 2024 (Values in Cr)
Book Value / Share 12.38
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.00
EBITDA Margin -951.97
Particulars MAR 2023 (Values in Cr)
Book Value / Share 17.21
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.01
EBITDA Margin -822.08
Particulars MAR 2022 (Values in Cr)
Book Value / Share 6.61
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -987.58
Particulars MAR 2021 (Values in Cr)
Book Value / Share 5.58
ROE % 0.00
ROCE % 0.00
Total Debt to Total Equity 0.04
EBITDA Margin -535.53
Particulars MAR 2025 (Values in Cr)
Book Value / Share 36.66
ROE % -6.33
ROCE % -6.30
Total Debt to Total Equity 0.00
EBITDA Margin -692.04
Particulars MAR 2024 (Values in Cr)
Book Value / Share 38.77
ROE % -2.36
ROCE % -2.44
Total Debt to Total Equity 0.00
EBITDA Margin -122.16
Particulars MAR 2023 (Values in Cr)
Book Value / Share 39.14
ROE % -4.20
ROCE % -4.11
Total Debt to Total Equity 0.00
EBITDA Margin -154.87
Particulars MAR 2022 (Values in Cr)
Book Value / Share 32.74
ROE % -9.17
ROCE % -8.90
Total Debt to Total Equity 0.01
EBITDA Margin -297.38
Particulars MAR 2021 (Values in Cr)
Book Value / Share 28.66
ROE % -5.73
ROCE % -6.73
Total Debt to Total Equity 0.01
EBITDA Margin -168.40
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 37.72
Total Assets 135.18
Total Liabilities 135.18
Total Equity 109.98
Share Outstanding 218073717
Price to Book Ratio 3.09
Return on Assets (%) -118.90
Return on Capital (%) -146.15
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 163.97
Total Assets 284.90
Total Liabilities 284.90
Total Equity 270.04
Share Outstanding 218073717
Price to Book Ratio 2.57
Return on Assets (%) -36.88
Return on Capital (%) -38.91
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 184.28
Total Assets 388.91
Total Liabilities 388.91
Total Equity 375.31
Share Outstanding 218073717
Price to Book Ratio 1.24
Return on Assets (%) -30.41
Return on Capital (%) -31.51
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 5.52
Total Assets 108.03
Total Liabilities 108.03
Total Equity 96.14
Share Outstanding 145382478
Price to Book Ratio 2.83
Return on Assets (%) -112.92
Return on Capital (%) -126.25
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 46.64
Total Assets 128.41
Total Liabilities 128.41
Total Equity 108.00
Share Outstanding 127282478
Price to Book Ratio 2.46
Return on Assets (%) -56.18
Return on Capital (%) -65.99
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 19.96
Total Assets 808.89
Total Liabilities 808.89
Total Equity 799.51
Share Outstanding 218073717
Price to Book Ratio 3.09
Return on Assets (%) -5.82
Return on Capital (%) -5.89
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 153.44
Total Assets 851.48
Total Liabilities 851.48
Total Equity 845.37
Share Outstanding 218073717
Price to Book Ratio 2.57
Return on Assets (%) -0.94
Return on Capital (%) -0.95
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 173.95
Total Assets 860.44
Total Liabilities 860.44
Total Equity 853.44
Share Outstanding 218073717
Price to Book Ratio 1.24
Return on Assets (%) -2.33
Return on Capital (%) -2.36
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 3.14
Total Assets 486.35
Total Liabilities 486.35
Total Equity 475.97
Share Outstanding 145382478
Price to Book Ratio 2.83
Return on Assets (%) -7.45
Return on Capital (%) -7.61
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 38.59
Total Assets 415.38
Total Liabilities 415.38
Total Equity 401.65
Share Outstanding 127282478
Price to Book Ratio 2.46
Return on Assets (%) -5.44
Return on Capital (%) -5.62
Particulars MAR 2025 (Values in Cr)
Net Income -160.74
Cash from Operations -154.70
Cash from Investing 154.95
Cash from Financing -0.75
Net change in Cash 0.09
Free Cash Flow -117.43
Particulars MAR 2024 (Values in Cr)
Net Income -106.07
Cash from Operations -121.64
Cash from Investing 94.43
Cash from Financing -1.05
Net change in Cash -22.08
Free Cash Flow -121.64
Particulars MAR 2023 (Values in Cr)
Net Income -118.26
Cash from Operations -114.87
Cash from Investing -247.81
Cash from Financing 395.53
Net change in Cash 31.74
Free Cash Flow -111.98
Particulars MAR 2022 (Values in Cr)
Net Income -121.99
Cash from Operations -127.01
Cash from Investing -22.22
Cash from Financing 145.69
Net change in Cash -4.07
Free Cash Flow -107.24
Particulars MAR 2021 (Values in Cr)
Net Income -77.47
Cash from Operations -94.87
Cash from Investing 55.84
Cash from Financing 34.85
Net change in Cash -5.32
Free Cash Flow -88.57
Particulars MAR 2025 (Values in Cr)
Net Income -47.07
Cash from Operations -47.99
Cash from Investing 44.21
Cash from Financing -0.75
Net change in Cash -3.93
Free Cash Flow -10.71
Particulars MAR 2024 (Values in Cr)
Net Income -9.01
Cash from Operations -26.73
Cash from Investing -0.67
Cash from Financing -1.05
Net change in Cash -22.29
Free Cash Flow -26.73
Particulars MAR 2023 (Values in Cr)
Net Income -20.12
Cash from Operations -21.81
Cash from Investing -348.82
Cash from Financing 395.53
Net change in Cash 23.79
Free Cash Flow -18.92
Particulars MAR 2022 (Values in Cr)
Net Income -36.24
Cash from Operations -36.10
Cash from Investing -107.45
Cash from Financing 145.69
Net change in Cash 1.60
Free Cash Flow -16.33
Particulars MAR 2021 (Values in Cr)
Net Income -27.95
Cash from Operations -35.53
Cash from Investing 2.41
Cash from Financing 34.85
Net change in Cash 0.58
Free Cash Flow -29.23
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7882.85 72.04 13.81 113343.29 6002.15 / 7920.40
FORTIS MALAR HOSPITALS LIMITED 68.52 27.85 4.25 128.42 51.01 / 98.70
SHREE PACETRONIX LTD. 151.64 52.29 3.96 54.58 61.11 / 221.50
TRANSGENE BIOTEK LTD. 4.40 0.00 3.32 33.34 3.22 / 9.55
Company Name Price P/E P/B Market Cap 52 Week Low/High
APOLLO HOSPITALS ENTER. L 7882.85 83.87 12.97 113343.29 6002.15 / 7920.40
Surlux Diagnostic Ltd 1.40 0.84 0.13 0.49 0.00 / 0.00
CHENNAI MEENAKSHI MULTISPECIAL 34.83 0.00 -13.76 26.02 28.34 / 59.90
KOVAI MEDICAL CENTER & HOSPITA 6351.45 31.52 6.39 6948.49 4777.15 / 6525.00

Suven Life Sciences Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
230.30 -1.72 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 235.50
  • 26 Days 251.90
  • 10 Days 240.70
  • 50 Days 246.90
  • 12 Days 243.00
  • 100 Days 222.00
  • 20 Days 249.70
  • 200 Days 188.40
237.25 PIVOT

First Support

230.50

First Resistance

241.50

Second Support

226.25

Second Resistance

248.25

Third Support

219.50

Third Resistance

252.50

RSI

37.07

ADX

42.86

MACD

-8.71

Williams % R

-85.38

Commodity Channel Index (CCI)

-87.74

Date

2025-06-16

Week

642717.00

Same Day

451936.00

Month

534645.00

1 Year

0.96

3 Year

0.93

Over 1 Month

-18.03%

down

Over 1 Year

61.99%

down

Over 3 Months

14.15%

down

Over 3 Years

54.86%

down

Over 6 Months

98.18%

down

Over 5 Years

38.64%

down

Transparent Pricing, 360° Services

Choose a plan that best suits your goals & needs.

greenshadow greenshadow redshadow pricing-pack Freedom Pack
₹20/order 14.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : FREE

greenshadow greenshadow redshadow pricing-pack

Professional Pack

₹10/order 11.99% p.a. MTF
tick Expert Stock Research tick Online Customer Support

Subscription Charge : 2500 Yearly

50% Brokerage Savings
greenshadow greenshadow redshadow pricing-pack

Signature

0.2% 11.99% p.a. MTF
tick Dedicated Relationship Manager tick Customised Brokerage Support tick Expert Stock Research tick Experienced Dealer Support

Suven Life Sciences shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
28.6%
Promoter Holdings
67.42%
FII
0.56%
DII
3.4%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Jasti Property And Equity Holdings Private Limited 1.516975E8 (66.75%) Shareholding of Promoter and Promoter Group
Quant Mutual Fund 4701490.0 (2.07%) Public Shareholding
Abakkus Diversified Alpha Fund 2985000.0 (1.31%) Public Shareholding
Sudharani Jasti 1528535.0 (0.67%) Shareholding of Promoter and Promoter Group
3p India Equity Fund 1 0.0 (0.0%) Public Shareholding
Madhavi Jasti 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Sirisha Jasti 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Kalyani Jasti 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Venkateswarlu Jasti 2201.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

Suven Life Sciences corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Feb 2019 1.5 Interim 15 Feb 2019 Equity shares
06 Feb 2018 1.5 Interim 07 Feb 2018 Equity shares
08 Feb 2017 1.0 Interim 09 Feb 2017 Equity shares
14 Mar 2016 1.0 Interim 15 Mar 2016 Equity shares
14 Mar 2016 1.0 Special 15 Mar 2016 Equity shares
23 Jul 2015 0.6 Final 25 Jul 2015 Equity shares
24 Jul 2014 0.5 Final 26 Jul 2014 Equity shares
24 Jul 2014 2.0 Special 26 Jul 2014 Equity shares
01 Aug 2013 0.3 Final 05 Aug 2013 Equity shares
17 Sep 2012 0.3 Final 19 Sep 2012 Equity shares
01 Aug 2011 0.25 Final 03 Aug 2011 Equity shares
19 Jul 2010 0.25 Final 21 Jul 2010 Equity shares
14 Sep 2009 0.25 Final 16 Sep 2009 Equity shares
11 Sep 2008 0.25 Final 13 Sep 2008 Equity shares
21 Sep 2007 0.25 Final 25 Sep 2007 Equity shares
25 Sep 2006 0.0 Final 27 Sep 2006 Equity shares
05 Sep 2005 0.0 Final 08 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
02 Apr 2007 23 Mar 2007 1:1
Ex-Date Old FV NEW FV Record Date
23 Mar 2007 2.0 1.0 02 Apr 2007
15 Jan 2004 10.0 2.0 23 Jan 2004
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Feb 2019 1.5 Interim 15 Feb 2019 Equity shares
06 Feb 2018 1.5 Interim 07 Feb 2018 Equity shares
08 Feb 2017 1.0 Interim 09 Feb 2017 Equity shares
14 Mar 2016 1.0 Interim 15 Mar 2016 Equity shares
14 Mar 2016 1.0 Special 15 Mar 2016 Equity shares
23 Jul 2015 0.6 Final 25 Jul 2015 Equity shares
24 Jul 2014 0.5 Final 26 Jul 2014 Equity shares
24 Jul 2014 2.0 Special 26 Jul 2014 Equity shares
01 Aug 2013 0.3 Final 05 Aug 2013 Equity shares
17 Sep 2012 0.3 Final 19 Sep 2012 Equity shares
01 Aug 2011 0.25 Final 03 Aug 2011 Equity shares
19 Jul 2010 0.25 Final 21 Jul 2010 Equity shares
14 Sep 2009 0.25 Final 16 Sep 2009 Equity shares
11 Sep 2008 0.25 Final 13 Sep 2008 Equity shares
21 Sep 2007 0.25 Final 25 Sep 2007 Equity shares
25 Sep 2006 0.0 Final 27 Sep 2006 Equity shares
05 Sep 2005 0.0 Final 08 Sep 2005 Equity shares
Ex-Date Ex-Bonus Ratio
02 Apr 2007 23 Mar 2007 1:1
Ex-Date Old FV NEW FV Record Date
23 Mar 2007 2.0 1.0 02 Apr 2007
15 Jan 2004 10.0 2.0 23 Jan 2004

Suven Life Sciences Share Price

Suven Life Sciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated in March, 1989. The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003. Promoted by Venkateswarlu Jasti, Company began its operations in 1989 as specialty chemicals provider.

The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies.

The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors. Suven's CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business.

In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr.

During 1999-2000, the company acquired a small pilot plant in Jeedimetla Industrial Estate, Hyderabad.

During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 have registered a growth of 71% over the previous year. The Profit After Tax (PAT) has also registered a growth of 325% over the previous year.

During the financial year ended 31 March 2014, Suven's Drug discovery portfolio has expanded into several new therapeutic areas such as Major Depressive Disorder (MDD), Obesity and Pain through Neuronal Nicotinic Receptor modulators. In addition, D-4010 and G3031 are undergoing regulatory toxicological studies in preparation for them being moving into Phase 1 clinical trial during 2014-15.

During the year 2014, Suven has made significant inroads into drug discovery with a specialization on CNS-based programmes targeting unmet medical needs. The Company enjoys a unique position in the India (and Asia) as one of the prominent company with technologies under central nervous system (CNS). It has funded drug discovery for nine years resulting in a robust pipeline of 14 molecules at various stages of development. Suven's discovery assets address niche therapeutic areas like cognition, depression, obesity and pain management.

In FY14, the Company filed one ANDA with the USFDA authorities for Malathion lotion, a head-lice product with sales potential estimated at US$35 million. In 2013-14, it granted the exclusive license to Taro Pharmaceuticals to market the product in the US, Canada and Mexico, which is expected to generate revenues and royalty in 2014-15.

During FY2015, Suven's lead clinical candidate SUVN-502 has successfully completed Phase 1b clinical trial thus paving the way for the co-pound to move into Proof of Concept (PoC) Phase 2a study. In addition to above compounds, SUVN D-4010 is in its final stages of completing regulatory toxicological studies which will enable it to move into Phase 1 clinical trial in USA.

During the FY2015, the Company has issued and allotted 104,53,690 equity shares of Re 1/- each at a premium of Rs 190.32 per share by way of QIP Issue in accordance with the SEBI ICDR guidelines.

During FY15, the Company's main focus stayed on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.

During FY15, the Company added two new clients to its CRAMS business. It commenced operations at its Vishakhapatnam unit and shifted the manufacturing intermediates for a specialty chemical product to this unit. The shift not only optimized capacities at its CRAMS facilities but also made the CRAMS operations more efficient.

During FY2017, the company has spent Rs. 6973 lakhs on innovative R&D in CNS therapies accounting for 13% on sales. Its focus remained on discovering, developing and commercializing novel pharmaceutical products, which are first in class CNS therapies through use of GPCR targets.

During FY 2017, the Company has invested a sum of Rs 6501 lakhs in Suven Neurosciences Inc., a wholly owned subsidiary, for its business purpose.

In FY2018, the company has spent Rs 6,390 lakhs on innovative R&D in CNS therapies accounting for 10% on sales.

The Company invested a sum of Rs.13,636 lakhs in Suven Neurosciences, Inc., for its business purpose. The Company acquired entire share capital of Rs.1 lakh in Suven Pharmaceuticals Limited identified as Resulting Company for the purpose of Scheme of Arrangement (Demerger) and as of 31st March, 2019 no investments were made in newly formed Suven Pharma, Inc. in USA.

During the FY 2018-2019, Suven Pharmaceuticals Limited in India and Suven Pharma, Inc., in USA became the subsidiary companies.

In 2018-19, the Company completed the Clinical Trial (Phase II) of the lead molecule SUVN-502, Masupirdine. In 2019-20, the Contract Research and Manufacturing Services (CRAMS) Undertaking of the Company was demerged to its wholly owned subsidiary, Suven Pharmaceuticals Limited as a going concern through a Scheme of Arrangement effective from 1st October, 2018.

In FY 2025, SUVN-I6107 launched for the treatment of cognitive impairment associated with neurodegenerative disorders. The scale-up of two lead-like compounds has been completed to support additional efficacy and safety profiling. It commissioned Serotonin and dopamine modulator for psychiatric disorders during the year. Suven engaged with the FDA to seek guidance on the design of the Phase 2 study for Usmarapride in 2025. The Company initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical trials for the investigational compound SUVN-G3031.

Parent organization Indian Private
NSE symbol SUVEN
Founded 1989
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Suven Life Sciences Ltd?

Answer Field

Suven Life Sciences Ltd share price is for NSE ₹ 230.75 & for BSE ₹ 231.00 as on Aug 22 2025 03:30 PM.

What is the Market Cap of Suven Life Sciences Ltd Share?

Answer Field

The market cap of Suven Life Sciences Ltd for NSE ₹ 5,032.05 & for BSE ₹ 5,037.50 as on Aug 22 2025 03:30 PM.

What is the 52 Week High and Low of Suven Life Sciences Ltd?

Answer Field

The 52 Week High and Low of Suven Life Sciences Ltd for NSE is ₹ 299.99 and ₹ 102.50 and for BSE is ₹ 303.00 and ₹ 102.70.

What is 1 year return for Suven Life Sciences Ltd?

Answer Field

The 1 year returns on the stock has been 59.15%.

What is the P/E Ratio of Suven Life Sciences Ltd Share?

Answer Field

As on Aug 22 2025 03:30 PM the price-to-earnings (PE) ratio for Suven Life Sciences Ltd share is -93.53.

What is the PB ratio of Suven Life Sciences Ltd Share?

Answer Field

As on Aug 22 2025 03:30 PM, the price-to-book (PB) ratio for Suven Life Sciences Ltd share is 36.66.

How to Buy Suven Life Sciences Ltd Share?

Answer Field

You can trade in Suven Life Sciences Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Suven Life Sciences Ltd Share on Bajaj Broking App?

Answer Field

To buy Suven Life Sciences Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Suven Life Sciences Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

close-image

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
close-image

Get Free Demat Account*

+91